Fractyl Health (GUTS) Preferred Dividend Payments (2023 - 2024)
Fractyl Health (GUTS) reported Preferred Dividend Payments of $1.7 million for Q1 2024, down 58.99% year-on-year from $4.2 million in Q2 2023, and down 59.88% quarter-over-quarter from $4.3 million in Q4 2023.
Fractyl Health (GUTS) has 2 years of Preferred Dividend Payments data on file, last reported at $1.7 million in Q1 2024.
- For the quarter ending Q1 2024, Preferred Dividend Payments fell 58.99% year-over-year to $1.7 million; the trailing twelve-month figure through Dec 2024 stood at $1.7 million (down 89.89% YoY), and the FY2024 full-year result was $1.7 million, down 89.89% from the prior year.
- Preferred Dividend Payments for Q1 2024 stood at $1.7 million, down from $4.3 million in the prior quarter.
- Across five years, Preferred Dividend Payments topped out at $4.3 million in Q3 2023 and bottomed at $1.7 million in Q1 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Pref Dividends (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - | - |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | - |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn | - |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn | - |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn | - |
| 10 | Fractyl Health | 19.24 Mn | 19.24 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 1.74 Mn |
| Dec 31, 2023 | 4.33 Mn |
| Sep 30, 2023 | 4.33 Mn |
| Jun 30, 2023 | 4.28 Mn |
| Mar 31, 2023 | 4.24 Mn |